Cue Biopharma logo

Cue BiopharmaNASDAQ: CUE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 January 2018

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$93.32 M
-83%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector
-51%vs. 3y high
79%vs. sector
-97%vs. 3y high
76%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:12:23 GMT
$1.55-$0.14(-8.28%)

Dividend

No data over the past 3 years
$2.66 M$1.52 M
$2.66 M-$10.17 M

Analysts recommendations

Institutional Ownership

CUE Latest News

Cue Biopharma Announces Pricing of $12.0 Million Public Offering
globenewswire.com26 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the pricing of an underwritten public offering of (i) 11,564,401 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 2,891,100 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 12,435,599 shares of common stock and accompanying common stock warrants to purchase an aggregate of 3,108,900 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.50, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.499. The aggregate gross proceeds of the offering are expected to be approximately $12.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.50 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about September 30, 2024, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Announces Proposed Public Offering
globenewswire.com26 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Announces Proposed Public Offering
globenewswire.com26 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
globenewswire.com09 September 2024 Sentiment: POSITIVE

BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO).

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript
seekingalpha.com19 August 2024 Sentiment: NEUTRAL

Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2024 Earnings Conference Call August 19, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Ren Benjamin - Citizens JMP Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Edward Tenthoff - Piper Sandler Operator Good day, and welcome to the Cue Biopharma Second Quarter 2024 Earnings Call. All participants will be in a listen-only mode.

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com19 August 2024 Sentiment: POSITIVE

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024.

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research15 April 2024 Sentiment: POSITIVE

Cue Biopharma (CUE) has identified a hammer chart pattern, suggesting that the stock has found support following a recent decline in value. This, along with an increase in earnings estimate revisions, could signal a potential turnaround for the stock in the near future.

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript
Seeking Alpha08 April 2024 Sentiment: POSITIVE

Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2023 Earnings Conference Call April 8, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Stephen Willey - Stifel Ren Benjamin - JMP Operator Greetings and welcome to the Cue Biopharma Investor Update call. At this time, all participants are in listen-only mode.

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
GlobeNewsWire22 November 2023 Sentiment: POSITIVE

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript
Seeking Alpha11 November 2023 Sentiment: POSITIVE

Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.

What type of business is Cue Biopharma?

Cue Biopharma Inc is a biopharmaceutical company working in the clinical stage. It is developing a new patented class of biological drugs for selective modulation of the human immune system to treat a wide range of cancers and autoimmune diseases. Its lead drug candidate includes CUE-101, a variant form of interleukin-2 cytokine and T-cell antigen for targeting and activating cancer-specific T cells associated with HPV-related cancer. Other products in development include CUE-102, CUE-103, CUE-400, and CUE-401. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

What sector is Cue Biopharma in?

Cue Biopharma is in the Healthcare sector

What industry is Cue Biopharma in?

Cue Biopharma is in the Biotechnology industry

What country is Cue Biopharma from?

Cue Biopharma is headquartered in United States

When did Cue Biopharma go public?

Cue Biopharma initial public offering (IPO) was on 02 January 2018

What is Cue Biopharma website?

https://www.cuebiopharma.com

Is Cue Biopharma in the S&P 500?

No, Cue Biopharma is not included in the S&P 500 index

Is Cue Biopharma in the NASDAQ 100?

No, Cue Biopharma is not included in the NASDAQ 100 index

Is Cue Biopharma in the Dow Jones?

No, Cue Biopharma is not included in the Dow Jones index

When was Cue Biopharma the previous earnings report?

No data

When does Cue Biopharma earnings report?

The next expected earnings date for Cue Biopharma is 08 November 2024